ArticleEuropean journal of orthopaedic surgery & traumatology : orthopedie traumatologie2025
Topical nitroglycerin for high-risk orthopaedic trauma wounds: a feasibility study on safety and wound healing outcomes.
Article in European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNitropaste, a topical nitroglycerin ointment, is recognized for its vasodilatory properties, which may enhance wound perfusion and reduce necrosis. Although widely used in plastic surgery, its application in orthopaedic surgery remains unexplored. This study evaluates the safety and feasibility of nitropaste during primary wound closure in high-risk lower extremity fractures.
methodsA retrospective review was conducted at a Level I Trauma Center on patients who underwent ORIF for tibial plateau, pilon, and calcaneal fractures between January 2016 and March 2024. Patients who received a single 15 mg intraoperative dose of nitropaste at wound closure were identified. Outcomes included wound dehiscence, infection, and systemic adverse effects.
resultsAmong 18 patients (14 males, 4 females; mean age 51.2 ± 12.2 years), fracture distribution included 11 pilon, 6 tibial plateau, and 1 calcaneal fractures. No systemic adverse effects were reported. Wound healing was uneventful in 15 patients (83.3%), while 3 (16.7%) developed wound dehiscence and infection, necessitating reoperation. Importantly, the wound complication rate aligns with historical benchmarks for these fractures, suggesting nitropaste does not increase risk.
conclusionsThis feasibility study demonstrates a favorable safety profile and supports nitropaste's potential role in wound healing. Larger prospective studies with standardized dosing protocols are needed to define its clinical efficacy and optimize its use in high-risk orthopaedic wounds.
Indexed as
Identifiers
40548981What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.